Ultrasound in Medicine and Biology
Volume 36, Issue 4 , Pages 604-609 , April 2010

Detection of MPTP-Induced Substantia Nigra Hyperechogenicity in Rhesus Monkeys by Transcranial Ultrasound

  • Thyagarajan Subramanian

      Affiliations

    • Departments of Neurology and Neural & Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • Corresponding Author InformationAddress correspondence to: Thyagarajan Subramanian, M.D., H109, Neurology and Neural & Behavioral Sciences, Penn State University Hershey Medical Center, 500 University Drive, Hershey, PA 17033.
    • ,
  • Christopher A. Lieu

      Affiliations

    • Departments of Neurology and Neural & Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • ,
  • Kumaraswamy Guttalu

      Affiliations

    • Departments of Neurology and Neural & Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, PA, USA
    • ,
  • Daniela Berg

      Affiliations

    • Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany

Received 31 August 2009 ,Revised 20 November 2009 ,Accepted 3 December 2009.

References 

  1. Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci. 1986;39:7–16
  2. Behnke S, Berg D, Naumann M, Becker G. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. J Neurol Neurosurg Psychiatry. 2005;76:423–425
  3. Berg D. In vivo detection of iron and neuromelanin by transcranial sonography–A new approach for early detection of substantia nigra damage. J Neural Transm. 2006;113:775–780
  4. Berg D. Transcranial sonography in the early and differential diagnosis of Parkinson's disease. J Neural Transm Suppl. 2006;249–254
  5. Berg D. Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: Implications for idiopathic and monogenetic forms. Neurochem Res. 2007;32:1646–1654
  6. Berg D. Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener Dis. 2008;5:133–136
  7. Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, et al. Brain iron pathways and their relevance to Parkinson's disease.[erratum appears in J Neurochem 2002;80:719]. J Neurochem. 2001;79:225–236
  8. Berg D, Godau J, Walter U. Transcranial sonography in movement disorders. Lancet Neurol. 2008;7:1044–1055
  9. Berg D, Grote C, Rausch WD, Maurer M, Wesemann W, Riederer P, et al. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol. 1999;25:901–904
  10. Berg D, Hochstrasser H, Schweitzer KJ, Riess O. Disturbance of iron metabolism in Parkinson's disease – Ultrasonography as a biomarker. Neurotox Res. 2006;9:1–13
  11. Berg D, Jabs B, Merschdorf U, Beckmann H, Becker G. Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. Biol Psychiatry. 2001;50:463–467
  12. Berg D, Merz B, Reiners K, Naumann M, Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord. 2005;20:383–385
  13. Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P, et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol. 2002;59:999–1005
  14. Berg D, Siefker C, Becker G. Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol. 2001;248:684–689
  15. Eberling JL, Jagust WJ, Taylor S, Bringas J, Pivirotto P, VanBrocklin HF, et al. A novel MPTP primate model of Parkinson's disease: Neurochemical and clinical changes. Brain Res. 1998;805:259–262
  16. Fowler KA, Huerkamp MJ, Pullium JK, Subramanian T. Anesthetic protocol: Propofol use in Rhesus macaques (Macaca mulatta) during magnetic resonance imaging with stereotactic head frame application. Brain Res Brain Res Protoc. 2001;7:87–93
  17. Gaenslen A, Unmuth B, Godau J, Liepelt I, Di Santo A, Schweitzer KJ, et al. The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: A prospective blinded study. Lancet Neurol. 2008;7:417–424
  18. He Y, Thong PS, Lee T, Leong SK, Mao BY, Dong F, et al. Dopaminergic cell death precedes iron elevation in MPTP-injected monkeys. Free Radic Biol Med. 2003;35:540–547
  19. Oiwa Y, Eberling JL, Nagy D, Pivirotto P, Emborg ME, Bankiewicz KS. Overlesioned hemiparkinsonian non human primate model: Correlation between clinical, neurochemical and histochemical changes. Front Biosci. 2003;8:a155–a166
  20. Prestel J, Schweitzer KJ, Hofer A, Gasser T, Berg D. Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. Mov Disord. 2006;21:1763–1765
  21. Ruprecht-Dorfler P, Berg D, Tucha O, Benz P, Meier-Meitinger M, Alders GL, et al. Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. Neuroimage. 2003;18:416–422
  22. Ruprecht-Dorfler P, Klotz P, Becker G, Berg D. Substantia nigra hyperechogenicity correlates with subtle motor dysfunction in tap dancers. Parkinsonism Relat Disord. 2007;13:362–364
  23. Schweitzer KJ, Brussel T, Leitner P, Kruger R, Bauer P, Woitalla D, et al. Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. J Neurol. 2007;254:613–616
  24. Schweitzer KJ, Hilker R, Walter U, Burghaus L, Berg D. Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease. Mov Disord. 2006;21:94–98
  25. Stockner H, Iranzo A, Seppi K, Serradell M, Gschliesser V, Sojer M, et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord. 2009;
  26. Subramanian T, Deogaonkar M, Brummer M, Bakay R. MRI guidance improves accuracy of stereotaxic targeting for cell transplantation in parkinsonian monkeys. Exp Neurol. 2005;193:172–180
  27. Subramanian T, Emerich DF, Bakay RA, Hoffman JM, Goodman MM, Shoup TM, et al. Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-Dopa uptake and metabolism after intracerebral implantation in nonhuman primates. Cell Transplant. 1997;6:469–477
  28. Walter U, Dressler D, Lindemann C, Slachevsky A, Miranda M. Transcranial sonography findings in welding-related parkinsonism in comparison to Parkinson's disease. Mov Disord. 2008;23:141–145
  29. Walter U, Dressler D, Probst T, Wolters A, Abu-Mugheisib M, Wittstock M, et al. Transcranial brain sonography findings in discriminating between parkinsonism and idiopathic Parkinson disease. Arch Neurol. 2007;64:1635–1640
  30. Walter U, Dressler D, Wolters A, Wittstock M, Benecke R. Transcranial brain sonography findings in clinical subgroups of idiopathic Parkinson's disease. Mov Disord. 2007;22:48–54
  31. Walter U, Niehaus L, Probst T, Benecke R, Meyer BU, Dressler D. Brain parenchyma sonography discriminates Parkinson's disease and atypical parkinsonian syndromes. Neurology. 2003;60:74–77
  32. Walter U, Wagner S, Horowski S, Benecke R, Zettl UK. Transcranial brain sonography findings predict disease progression in multiple sclerosis. Neurology. 2009;73:1010–1017
  33. Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M, et al. In vivo detection of iron and neuromelanin by transcranial sonography: A new approach for early detection of substantia nigra damage. Mov Disord. 2005;20:1278–1285

PII: S0301-5629(09)01678-0

doi: 10.1016/j.ultrasmedbio.2009.12.001

Ultrasound in Medicine and Biology
Volume 36, Issue 4 , Pages 604-609 , April 2010

Article Tools

* Image Usage & Resolution